- Home
- CHY vs NUVB Comparison
CHY vs NUVB Comparison
Compare CHY & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHY
- NUVB
- Stock Information
- Founded
- CHY 2003
- NUVB 2018
- Country
- CHY United States
- NUVB United States
- Employees
- CHY N/A
- NUVB N/A
- Industry
- CHY Investment Managers
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- CHY Finance
- NUVB Health Care
- Exchange
- CHY Nasdaq
- NUVB Nasdaq
- Market Cap
- CHY 934.9M
- NUVB 831.3M
- IPO Year
- CHY N/A
- NUVB N/A
- Fundamental
- Price
- CHY $11.32
- NUVB $2.42
- Analyst Decision
- CHY
- NUVB Strong Buy
- Analyst Count
- CHY 0
- NUVB 6
- Target Price
- CHY N/A
- NUVB $7.67
- AVG Volume (30 Days)
- CHY 128.3K
- NUVB 2.9M
- Earning Date
- CHY 01-01-0001
- NUVB 02-27-2025
- Dividend Yield
- CHY 10.11%
- NUVB N/A
- EPS Growth
- CHY N/A
- NUVB N/A
- EPS
- CHY N/A
- NUVB N/A
- Revenue
- CHY N/A
- NUVB $2,162,000.00
- Revenue This Year
- CHY N/A
- NUVB N/A
- Revenue Next Year
- CHY N/A
- NUVB $663.04
- P/E Ratio
- CHY N/A
- NUVB N/A
- Revenue Growth
- CHY N/A
- NUVB N/A
- 52 Week Low
- CHY $9.97
- NUVB $1.53
- 52 Week High
- CHY $12.16
- NUVB $4.16
- Technical
- Relative Strength Index (RSI)
- CHY 37.42
- NUVB 43.45
- Support Level
- CHY $11.07
- NUVB $2.23
- Resistance Level
- CHY $11.48
- NUVB $2.54
- Average True Range (ATR)
- CHY 0.19
- NUVB 0.18
- MACD
- CHY 0.00
- NUVB -0.03
- Stochastic Oscillator
- CHY 30.77
- NUVB 31.93
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high yield securities.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).